References
- Falco OB, Plewig G, Wolff HH, Burgdorf WHC. Erythemato-papulo-squamous diseases. In: Dermatology. 2nd ed; Berlin: Springer-Verlag. 2000:571–647.
- Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int. 2007; 99:274–280.
- Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JWC. Hand–foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008; 158:592–596.
- Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007; 7:127–134.
- Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008; 58:545–570.
- Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24:2505–2512.
- Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P. Cutaneous side effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005; 6:491–500.
- Robert C, Faivre S, Raymond E, Armand JP, Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med. 2005; 143:313–314.
- Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, Stadlert WM. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine- kinase inhibitor. Clin Exp Dermatol. 2006; 31:783–785.
- MacGregor JL, Silvers DN, Grossman ME, Sherman WH. Sorafenib-induced erythema multiforme. J Am Acad Dermatol. 2007; 56:527–528.